Compare · HYFT vs NVO
HYFT vs NVO
Side-by-side comparison of MindWalk Holdings Corp. (HYFT) and Novo Nordisk A/S (NVO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both HYFT and NVO operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $173.66B, about 2633.0x HYFT ($66.0M).
- Over the past year, HYFT is down 19.6% and NVO is down 30.4% - HYFT leads by 10.7 points.
- HYFT has been more active in the news (7 items in the past 4 weeks vs 3 for NVO).
- NVO has more recent analyst coverage (25 ratings vs 0 for HYFT).
- Company
- MindWalk Holdings Corp.
- Novo Nordisk A/S
- Price
- $1.31-7.09%
- $38.82-1.05%
- Market cap
- $66.0M
- $173.66B
- 1M return
- +0.77%
- -10.14%
- 1Y return
- -19.63%
- -30.36%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- News (4w)
- 7
- 3
- Recent ratings
- 0
- 25
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest HYFT
- SEC Form 6-K filed by MindWalk Holdings Corp.
- AI-Designed Biologics Are Moving From the Screen to the Bench, and Developers Are Hiring for the Next Test
- MindWalk Holdings Corp. Strengthens Boston-Based Development Leadership as Pipeline Advances Toward Preclinical Efficacy Studies
- SEC Form 6-K filed by MindWalk Holdings Corp.
- MindWalk (NASDAQ: HYFT): Enterprise AI Has Found Its Ontology Layer. Biology Needs One Grounded in Biological Function
- SEC Form 6-K filed by MindWalk Holdings Corp.
- MindWalk Appoints Kim Remizowski to Board of Directors as Independent Director
- Chipmakers Now Ship Protein-Folding AI as Plug-and-Play Microservices
- SEC Form 6-K filed by MindWalk Holdings Corp.
- SEC Form 6-K filed by MindWalk Holdings Corp.
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Novo Nordisk A/S downgraded by Morgan Stanley with a new price target
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Novo Nordisk A/S downgraded by Deutsche Bank